Clinical Trials Logo

Clinical Trial Summary

This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT. IPT is caused by swelling in the retina (the light sensitive tissue in the back of the eye) due to leaky blood vessels in this area. Swelling in the retina can lead to blurry vision.


Clinical Trial Description

This study is a randomized, interventional case series. A total of 10 patients, seen in the Retina Division of the Wilmer Eye Institute, will be enrolled. Subjects will be randomized to either 0.3 mg or 0.5 mg intravitreal injections of ranibizumab. Patients with IPT with macular edema documented on optical coherence tomography (OCT) but no choroidal neovascularization will be eligible for this study. Exclusion criteria will include other forms of retinopathy, active intraocular inflammation, history of poor vision due to conditions other than IPT in either eye, and known hypersensitivity to humanized monoclonal antibodies.

After obtaining informed consent, the patient will undergo baseline assessment including best-corrected Early Treatment for Diabetic Retinopathy Study (ETDRS) visual acuity, ocular examination, color fundus photography, fluorescein angiography, and OCT. If both eyes are eligible, the study participant and investigator will choose which eye to be considered the study eye. The study eye will be assigned at random to receive an intravitreal dose of ranibizumab (0.3 mg/0.05 ml or 0.5 mg/0.05 ml) at the baseline, 1 month, and 2 month visits. Further monthly injections are at the discretion of the examiner, and may be withheld if there is lack of continued improvement (defined as lack of improvement of at least 5 letters on an eye chart compared with 2 previous consecutive visits or lack of decrease of the retinal center point thickness of at least 50 microns compared with 2 previous consecutive visits) or complete success (defined as visual acuity of 20/20 or better or retinal center point thickness <225 microns). ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00378196
Study type Interventional
Source Johns Hopkins University
Contact
Status Completed
Phase Phase 1
Start date September 2006
Completion date December 2008

See also
  Status Clinical Trial Phase
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Terminated NCT04336163 - Skin Imaging to Inform Laser Treatments N/A
Completed NCT02286804 - Ultherapy for the Treatment of Spider Veins on the Legs N/A
Completed NCT03472859 - Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser N/A
Completed NCT01491620 - Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte N/A
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Completed NCT04148950 - Effects of Kinesio Taping Method on Functional Capacity and Quality of Life in Patients With Chronic Venous Disease N/A
Completed NCT00457067 - Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation Phase 1
Completed NCT00457145 - Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation Phase 1
Completed NCT04795310 - Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia N/A
Completed NCT04274842 - D-OCT of Facial Telangiectasia Treated With IPL N/A
Recruiting NCT05978986 - Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence N/A
Completed NCT05036200 - Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma N/A